RARE logo

Ultragenyx Pharmaceutical (RARE) Selling, General & Administrative Expenses

Annual SG&A

$309.80 M
+$31.66 M+11.38%

31 December 2023

3-Year Change

+40.83%
RARE annual selling, general & administrative expenses is up +40.83% over the past 3 years

All-time High

$309.80 M
RARE annual selling, general & administrative expenses is currently at an all-time high

Sector Rank

86.06%
RARE annual selling, general & administrative expenses is higher than 86.06% of companies in Healthcare sector
Annual Total Expenses$1.00 B
RARE annual total expenses is $1.00 billion
Annual Operating Expenses$958.25 M
RARE annual total operating expenses is $958.25 million
Annual Revenue$434.25 M
RARE annual revenue is $434.25 million
Annual Net Income-$606.64 M
RARE annual net profit is -$606.64 million

RARE Selling, General & Administrative Expenses Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Quarterly SG&A

$80.35 M
-$253.00 K-0.31%

30 September 2024

1-Year Change

+4.58%
RARE quarterly selling, general & administrative expenses is up +4.58% year-on-year

3-Year Change

+35.2%
RARE quarterly selling, general & administrative expenses is up +35.2% over the past 3 years

All-time High

$81.40 M
RARE quarterly selling, general & administrative expenses is currently -1.29% below its historical high of $81.40 million

Sector Rank

85.76%
RARE quarterly selling, general & administrative expenses is higher than 85.76% of companies in Healthcare sector
Quarterly Total Expenses$271.48 M
RARE quarterly total expenses is $271.48 million
Quarterly Operating Expenses$250.46 M
RARE quarterly total operating expenses is $250.46 million
Quarterly Revenue$139.49 M
RARE quarterly revenue is $139.49 million
Quarterly Net Income-$133.52 M
RARE quarterly net profit is -$133.52 million

RARE Quarterly SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

TTM SG&A

-$14.46 B
-$558.99 M-4.02%

30 September 2024

1-Year Change

-4767.35%
RARE TTM selling, general & administrative expenses is down -4767.35% year-on-year

3-Year Change

-6673%
RARE TTM selling, general & administrative expenses is down -6673% over the past 3 years

All-time High

$315.95 M
RARE TTM selling, general & administrative expenses is currently -4676.52% below its historical high of $315.95 million

Sector Rank

1.51%
RARE TTM selling, general & administrative expenses is higher than 1.51% of companies in Healthcare sector
Annual Total Expenses$1.00 B
RARE annual total expenses is $1.00 billion
Annual Operating Expenses$958.25 M
RARE annual total operating expenses is $958.25 million
TTM Revenue$522.75 M
RARE TTM revenue is $522.75 million
TTM Net Income-$558.99 M
RARE TTM net profit is -$558.99 million

RARE TTM SG&A Chart

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

RARE Selling, General & Administrative Expenses Performance

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-+4.6%-4767.4%
3 y3 years+40.8%+35.2%-6673.0%
5 y5 years+91.8%+91.9%-9051.9%

RARE Selling, General & Administrative Expenses High & Low

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3 yearsat high+40.8%-1.3%+35.2%-88.8%at low
5 y5 yearsat high+91.8%-1.3%+91.9%-182.1%at low
alltimeall timeat high>+9999.0%-1.3%+8798.2%<-9999.0%at low

Ultragenyx Pharmaceutical Selling, General & Administrative Expenses History

DateAnnualQuarterlyTTM
Sept 2024
-
$80.35 M(-0.3%)
$315.95 M(+1.8%)
June 2024
-
$80.60 M(+3.1%)
$310.51 M(-0.3%)
Mar 2024
-
$78.16 M(+1.7%)
$311.31 M(+0.5%)
Dec 2023
$309.80 M(+11.4%)
$76.83 M(+2.6%)
$309.80 M(+1.3%)
Sept 2023
-
$74.92 M(-8.0%)
$305.81 M(+1.7%)
June 2023
-
$81.40 M(+6.2%)
$300.74 M(+4.6%)
Mar 2023
-
$76.65 M(+5.2%)
$287.47 M(+3.4%)
Dec 2022
$278.14 M(+26.4%)
$72.85 M(+4.3%)
$278.14 M(+5.1%)
Sept 2022
-
$69.84 M(+2.5%)
$264.72 M(+6.4%)
June 2022
-
$68.14 M(+1.2%)
$248.76 M(+6.3%)
Mar 2022
-
$67.31 M(+13.3%)
$234.04 M(+6.4%)
Dec 2021
$219.98 M(+20.3%)
$59.43 M(+10.3%)
$219.98 M(+4.0%)
Sept 2021
-
$53.88 M(+0.9%)
$211.59 M(+5.9%)
June 2021
-
$53.41 M(+0.3%)
$199.83 M(+5.9%)
Mar 2021
-
$53.26 M(+4.3%)
$188.68 M(+3.1%)
Dec 2020
$182.93 M(+13.3%)
$51.04 M(+21.2%)
$182.93 M(+5.3%)
Sept 2020
-
$42.12 M(-0.3%)
$173.77 M(+0.6%)
June 2020
-
$42.25 M(-11.1%)
$172.65 M(+1.4%)
Mar 2020
-
$47.52 M(+13.5%)
$170.21 M(+5.4%)
Dec 2019
$161.52 M(+26.5%)
$41.88 M(+2.1%)
$161.52 M(+4.8%)
Sept 2019
-
$41.01 M(+3.0%)
$154.12 M(+6.9%)
June 2019
-
$39.81 M(+2.5%)
$144.21 M(+6.7%)
Mar 2019
-
$38.83 M(+12.6%)
$135.12 M(+5.8%)
Dec 2018
$127.72 M
$34.48 M(+10.9%)
$127.72 M(-2.5%)
DateAnnualQuarterlyTTM
Sept 2018
-
$31.09 M(+1.2%)
$130.97 M(+6.2%)
June 2018
-
$30.72 M(-2.3%)
$123.37 M(+9.5%)
Mar 2018
-
$31.43 M(-16.7%)
$112.66 M(+12.8%)
Dec 2017
$99.91 M(+53.9%)
$37.72 M(+60.5%)
$99.91 M(+21.8%)
Sept 2017
-
$23.50 M(+17.5%)
$82.00 M(+8.3%)
June 2017
-
$20.00 M(+7.1%)
$75.68 M(+7.5%)
Mar 2017
-
$18.68 M(-5.7%)
$70.41 M(+8.4%)
Dec 2016
$64.94 M(+96.8%)
$19.81 M(+15.3%)
$64.94 M(+14.5%)
Sept 2016
-
$17.18 M(+16.6%)
$56.72 M(+14.0%)
June 2016
-
$14.74 M(+11.6%)
$49.77 M(+18.3%)
Mar 2016
-
$13.21 M(+13.9%)
$42.07 M(+27.5%)
Dec 2015
$33.00 M(+205.3%)
$11.59 M(+13.3%)
$33.00 M(+32.9%)
Sept 2015
-
$10.23 M(+45.4%)
$24.83 M(+41.2%)
June 2015
-
$7.04 M(+70.1%)
$17.58 M(+35.6%)
Mar 2015
-
$4.14 M(+20.9%)
$12.96 M(+19.9%)
Dec 2014
$10.81 M(+142.9%)
$3.42 M(+14.8%)
$10.81 M(+24.1%)
Sept 2014
-
$2.98 M(+23.1%)
$8.71 M(+29.5%)
June 2014
-
$2.42 M(+22.0%)
$6.73 M(+25.7%)
Mar 2014
-
$1.99 M(+50.3%)
$5.35 M(+20.3%)
Dec 2013
$4.45 M(+33.1%)
$1.32 M(+32.2%)
$4.45 M(+10.4%)
Sept 2013
-
$999.00 K(-4.7%)
$4.03 M(+32.9%)
June 2013
-
$1.05 M(-3.2%)
$3.03 M(+52.8%)
Mar 2013
-
$1.08 M(+19.9%)
$1.99 M(+119.9%)
Dec 2012
$3.34 M(+81.3%)
$903.00 K
$903.00 K
Dec 2011
$1.84 M
-
-

FAQ

  • What is Ultragenyx Pharmaceutical annual selling, general & administrative expenses?
  • What is the all time high annual SG&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly selling, general & administrative expenses?
  • What is the all time high quarterly SG&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical quarterly SG&A year-on-year change?
  • What is Ultragenyx Pharmaceutical TTM selling, general & administrative expenses?
  • What is the all time high TTM SG&A for Ultragenyx Pharmaceutical?
  • What is Ultragenyx Pharmaceutical TTM SG&A year-on-year change?

What is Ultragenyx Pharmaceutical annual selling, general & administrative expenses?

The current annual SG&A of RARE is $309.80 M

What is the all time high annual SG&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high annual selling, general & administrative expenses is $309.80 M

What is Ultragenyx Pharmaceutical quarterly selling, general & administrative expenses?

The current quarterly SG&A of RARE is $80.35 M

What is the all time high quarterly SG&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high quarterly selling, general & administrative expenses is $81.40 M

What is Ultragenyx Pharmaceutical quarterly SG&A year-on-year change?

Over the past year, RARE quarterly selling, general & administrative expenses has changed by +$3.52 M (+4.58%)

What is Ultragenyx Pharmaceutical TTM selling, general & administrative expenses?

The current TTM SG&A of RARE is -$14.46 B

What is the all time high TTM SG&A for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical all-time high TTM selling, general & administrative expenses is $315.95 M

What is Ultragenyx Pharmaceutical TTM SG&A year-on-year change?

Over the past year, RARE TTM selling, general & administrative expenses has changed by -$14.77 B (-4767.35%)